Resverlogix Corp
TSX:RVX

Watchlist Manager
Resverlogix Corp Logo
Resverlogix Corp
TSX:RVX
Watchlist
Price: 0.095 CAD -5% Market Closed
Market Cap: 27.3m CAD

Resverlogix Corp
Net Change in Cash

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Resverlogix Corp
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Resverlogix Corp
TSX:RVX
Net Change in Cash
$94k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Net Change in Cash
-$21.7m
CAGR 3-Years
5%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Net Change in Cash
-$7.7m
CAGR 3-Years
58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Net Change in Cash
$36m
CAGR 3-Years
8%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Net Change in Cash
$16.9m
CAGR 3-Years
3%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Spectral Medical Inc
TSX:EDT
Net Change in Cash
CA$133k
CAGR 3-Years
N/A
CAGR 5-Years
-51%
CAGR 10-Years
N/A
No Stocks Found

Resverlogix Corp
Glance View

Market Cap
27.3m CAD
Industry
Biotechnology

Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.

RVX Intrinsic Value
Not Available

See Also

What is Resverlogix Corp's Net Change in Cash?
Net Change in Cash
94k USD

Based on the financial report for Dec 31, 2024, Resverlogix Corp's Net Change in Cash amounts to 94k USD.

Back to Top